Q4 CY2025 as sales rose 4.7% year on year to $622 million. Its GAAP profit of $0.64 per share was 57.3% below analysts’ ...

As Johnson & Johnson weathers some hefty losses of exclusivity—plus a surprise revenue blow to its cancer star Imbruvica—the company is holding firm on its aggressive pharmaceutical sales target for ...

Explore Sun Pharma's strong portfolio, innovative launches, and investment potential amidst market volatility for long-term growth.

Gilead Sciences is coming off of a milestone year that saw the start of the much-anticipated launch of the world’s first twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) medicine Ye | ...

Pharmaceutical companies make drugs. Doctors, hospitals and other healthcare providers prescribe the drugs that patients need. In the middle sit pharma sales teams, whose role is to connect healthcare ...

Reported Standalone quarterly numbers for Sandu Pharmaceuticals are: Net Sales at Rs 18.76 crore in December 2025 up 2.11% from Rs. 18.37 crore in December 2024. Quarterly Net Profit at Rs. 0.98 crore ...

Reported Standalone quarterly numbers for Alembic Pharmaceuticals are: Net Sales at Rs 1,642.24 crore in December 2025 up ...

MANILA, Philippines – Generic medicines are projected to command more than half of the Philippines’ pharmaceutical market over the next four years, amid rising health-care costs that are expected to ...

The main market opportunities lie in understanding regulatory environments, approval procedures, and market trends across 70 key countries. By leveraging insights into healthcare systems, pricing, and ...

Novartis CEO Vas Narasimhan received $32.4 million in total realized compensation in 2025, a marked increase compared to his take home pay in 2024. Narasimhan received 24.9 million Swiss Francs last ...